Antonio Medina de Almeida


AuthID: R-000-T91

Confirmed Publications: 65



41
TITLE: Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
AUTHORS: Valeria Santini; Antonio Almeida ; Aristoteles Giagounidis; Stefanie Groepper; Anna Jonasova; Norbert Vey; Ghulam J Mufti; Rena Buckstein; Moshe Mittelman; Uwe Platzbecker; Ofer Shpilberg; Ron Ram; Consuelo del Canizo; Norbert Gattermann; Keiya Ozawa; Alberto Risueno; Kyle J MacBeth; Jianhua H Zhong; Francis Seguy; Albert Hoenekopp; Beach, CL; Pierre Fenaux; ...More
PUBLISHED: 2016, SOURCE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 34, ISSUE: 25
INDEXED IN: Scopus WOS CrossRef
IN MY: ORCID | CIÊNCIAVITAE
42
TITLE: Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry
AUTHORS: de Swart, L; Smith, A; Johnston, TW; Haase, D; Droste, J; Fenaux, P; Symeonidis, A; Sanz, G; Hellstrom Lindberg, E; Cermak, J; Germing, U; Stauder, R; Georgescu, O; MacKenzie, M; Malcovati, L; Holm, MS; Almeida, AM ; Madry, K; Slama, B; Guerci Bresler, A; Sanhes, L; Beyne Rauzy, O; Luno, E; Bowen, D; de Witte, T; ...More
PUBLISHED: 2015, SOURCE: BRITISH JOURNAL OF HAEMATOLOGY, VOLUME: 170, ISSUE: 3
INDEXED IN: Scopus WOS CrossRef
IN MY: ORCID | CIÊNCIAVITAE
43
TITLE: Cell-type-specific transcriptional regulation of PIGM underpins the divergent hematologic phenotype in inherited GPl deficiency
AUTHORS: Joana R Costa; Valentina S Caputo; Kalliopi Makarona; Mark M Layton; Irene A G Roberts; Antonio M Almeida ; Anastasios Karadimitris;
PUBLISHED: 2014, SOURCE: BLOOD, VOLUME: 124, ISSUE: 20
INDEXED IN: Scopus WOS CrossRef
IN MY: ORCID | CIÊNCIAVITAE
44
TITLE: Optimizing treatments in rare diseases: Will our evidence come from registry data?  Full Text
AUTHORS: Antonio M Almeida ;
PUBLISHED: 2014, SOURCE: LEUKEMIA RESEARCH, VOLUME: 38, ISSUE: 4
INDEXED IN: Scopus WOS CrossRef
IN MY: ORCID | CIÊNCIAVITAE
45
TITLE: Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDS  Full Text
AUTHORS: Pierdomenico, F; Esteves, S; Almeida, A ;
PUBLISHED: 2013, SOURCE: ANNALS OF HEMATOLOGY, VOLUME: 92, ISSUE: 9
INDEXED IN: Scopus WOS CrossRef
IN MY: ORCID | CIÊNCIAVITAE
46
TITLE: Modifying disease in CMML: Who responds to Azacitidine?  Full Text
AUTHORS: Antonio Almeida ;
PUBLISHED: 2013, SOURCE: LEUKEMIA RESEARCH, VOLUME: 37, ISSUE: 6
INDEXED IN: Scopus WOS CrossRef
IN MY: ORCID | CIÊNCIAVITAE
47
TITLE: Treatment of acute erythroleukemia with Azacitidine: A case series
AUTHORS: Pierdomenico, F; Almeida, A ;
PUBLISHED: 2013, SOURCE: Leukemia Research Reports, VOLUME: 2, ISSUE: 2
INDEXED IN: Scopus CrossRef
IN MY: ORCID | CIÊNCIAVITAE
48
49
50
TITLE: Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: A case series and literature review  Full Text
AUTHORS: Michael Thorpe; Ana Montalvao; Francesca Pierdomenico; Filipa Moita; Antonio Almeida ;
PUBLISHED: 2012, SOURCE: LEUKEMIA RESEARCH, VOLUME: 36, ISSUE: 8
INDEXED IN: Scopus WOS CrossRef
IN MY: ORCID | CIÊNCIAVITAE
Page 5 of 7. Total results: 65.

footer slogan

Useful Links

Get Help

© 2025 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service